MD4719B1 - Formă cristalină a sării de trietilamină a acidului tiazolilacetic substituit - Google Patents

Formă cristalină a sării de trietilamină a acidului tiazolilacetic substituit

Info

Publication number
MD4719B1
MD4719B1 MDA20150099A MD20150099A MD4719B1 MD 4719 B1 MD4719 B1 MD 4719B1 MD A20150099 A MDA20150099 A MD A20150099A MD 20150099 A MD20150099 A MD 20150099A MD 4719 B1 MD4719 B1 MD 4719B1
Authority
MD
Moldova
Prior art keywords
crystalline form
triethylamine salt
acid triethylamine
substituted
thiazolylacetic acid
Prior art date
Application number
MDA20150099A
Other languages
English (en)
Russian (ru)
Other versions
MD4719C1 (ro
MD20150099A2 (ro
Inventor
Вэйцзян ЧЖАН
Майкл Р. ТРЭЙСИ
Цзюньнин Ли
Original Assignee
Theravance Biopharma Antibiotics Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics Ip, Llc filed Critical Theravance Biopharma Antibiotics Ip, Llc
Publication of MD20150099A2 publication Critical patent/MD20150099A2/ro
Publication of MD4719B1 publication Critical patent/MD4719B1/ro
Publication of MD4719C1 publication Critical patent/MD4719C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Invenţia se referă la o formă cristalină a unei sări de trietilamină a acidului (2Z)-2-(2-amino-5-clortiazol-4-il)-2-(3-N-terţ-butoxicarbonilaminopropoxiimino)acetic cu formula (I):IInvenţia se mai referă la procedee şi compuşi intermediari pentru prepararea formei cristaline menţionate. Forma cristalină este utilă în calitate de compus intermediar pentru prepararea antibioticelor glicopeptid-cefalosporinice cu o legătură intermoleculară reticulată.
MDA20150099A 2013-03-13 2014-03-06 Formă cristalină a sării de trietilamină a acidului tiazolilacetic substituit MD4719C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779091P 2013-03-13 2013-03-13
PCT/US2014/021080 WO2014164187A1 (en) 2013-03-13 2014-03-06 Crystalline form of a substituted thiazolylacetic acid triethylamine salt

Publications (3)

Publication Number Publication Date
MD20150099A2 MD20150099A2 (ro) 2016-02-29
MD4719B1 true MD4719B1 (ro) 2020-10-31
MD4719C1 MD4719C1 (ro) 2021-05-31

Family

ID=50382685

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150099A MD4719C1 (ro) 2013-03-13 2014-03-06 Formă cristalină a sării de trietilamină a acidului tiazolilacetic substituit

Country Status (20)

Country Link
US (1) US9139542B2 (ro)
EP (1) EP2970164B1 (ro)
JP (2) JP6404309B2 (ro)
KR (1) KR20150126368A (ro)
CN (1) CN105121417B (ro)
AU (1) AU2014249611B2 (ro)
BR (1) BR112015022600A2 (ro)
CA (1) CA2902724A1 (ro)
EA (1) EA027911B1 (ro)
ES (1) ES2634019T3 (ro)
GE (1) GEP201706779B (ro)
HK (1) HK1214596A1 (ro)
IL (1) IL240600A0 (ro)
MD (1) MD4719C1 (ro)
MX (1) MX351963B (ro)
PH (1) PH12015502067A1 (ro)
SG (1) SG11201507221VA (ro)
TW (1) TWI627165B (ro)
UA (1) UA115087C2 (ro)
WO (1) WO2014164187A1 (ro)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014751A (es) * 2019-05-31 2022-01-18 Hyundai Pharm Co Ltd Forma cristalina novedosa de derivado de acido 3-(4-(benciloxi)fenil)hex-4-inoico.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372952A (en) 1978-07-31 1983-02-08 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4284631A (en) 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
DE2945248A1 (de) 1978-11-13 1980-05-22 Fujisawa Pharmaceutical Co Cephem-verbindungen, verfahren zu ihrer herstellung und sie enthaltende antibakterielle pharmazeutische mittel
DE3177090D1 (en) * 1980-12-31 1989-09-28 Fujisawa Pharmaceutical Co 7-acylaminocephalosporanic acid derivatives and processes for the preparation thereof
JP2519054B2 (ja) 1986-06-09 1996-07-31 武田薬品工業株式会社 新規セフェム化合物
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
JPH04221388A (ja) * 1990-12-20 1992-08-11 Asahi Chem Ind Co Ltd セファロスポリン化合物およびその製造法
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
ITMI20012363A1 (it) 2001-11-09 2003-05-09 Antibioticos Spa Metodo per la sintesi di catene laterali di cefalosporine
ES2384707T3 (es) 2002-05-24 2012-07-11 Theravance, Inc. Antibióticos entrecruzados de glucopéptidos y cefalosporinas
GB0416379D0 (en) 2004-07-22 2004-08-25 Sandoz Ag Organic compounds
TW200637559A (en) 2005-03-29 2006-11-01 Shionogi & Co 3-propenylcefem derivative

Also Published As

Publication number Publication date
CN105121417A (zh) 2015-12-02
AU2014249611B2 (en) 2017-12-21
SG11201507221VA (en) 2015-10-29
EP2970164A1 (en) 2016-01-20
WO2014164187A1 (en) 2014-10-09
MX2015012146A (es) 2015-11-25
CN105121417B (zh) 2017-11-17
EA027911B1 (ru) 2017-09-29
US20140275554A1 (en) 2014-09-18
TWI627165B (zh) 2018-06-21
MX351963B (es) 2017-11-06
US9139542B2 (en) 2015-09-22
ES2634019T3 (es) 2017-09-26
UA115087C2 (uk) 2017-09-11
BR112015022600A2 (pt) 2017-07-18
JP2018197256A (ja) 2018-12-13
CA2902724A1 (en) 2014-10-09
MD4719C1 (ro) 2021-05-31
MD20150099A2 (ro) 2016-02-29
EA201591708A1 (ru) 2016-01-29
JP6404309B2 (ja) 2018-10-10
TW201444810A (zh) 2014-12-01
GEP201706779B (en) 2017-11-27
EP2970164B1 (en) 2017-05-03
AU2014249611A1 (en) 2015-09-17
JP2016512257A (ja) 2016-04-25
IL240600A0 (en) 2015-09-24
PH12015502067B1 (en) 2016-01-25
HK1214596A1 (zh) 2016-07-29
KR20150126368A (ko) 2015-11-11
PH12015502067A1 (en) 2016-01-25

Similar Documents

Publication Publication Date Title
NZ726356A (en) Processes for preparing antiviral compounds
IN2014MN02496A (ro)
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
MX2015011723A (es) Proceso para la preparacion de una sal de sodio de (2s, 5r) -2-carboxamido-7-oxo-6-sulfooxi-1,6-diaza-biciclo[3.2.1]-octano.
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
MX359673B (es) Preparacion de intermediarios de pirimidina utiles para la preparacion de maci tentano.
PH12016501941B1 (en) Use of heterocyclic compounds for controlling nematodes
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
MX342273B (es) Proceso para la preparacion de esteres de acido (5-fluoro-2-metil-3-quinolina-2-ilmetil-indol-1-il)-acetico.
WO2016142819A3 (en) Novel process for the preparation of ranolazine
MY174153A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
IN2013DE02503A (ro)
PH12015502067A1 (en) Crystalline form of a substituted thiazolylacetic acid triethylamine salt
IN2013MU04056A (ro)
MX2014002378A (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
EP3936506A4 (en) ACID ADDITION SALT CRYSTAL FORM OF A PUROPYRIMIDINE COMPOUND
MX2016005511A (es) Intermediarios y metodos para sintetizar derivados de calicheamicina.
MX2014012822A (es) Proceso para elaborar derivados de naftiridina.
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
MX2015015346A (es) Procedimiento para la preparacion de intermediarios de acido boronico.
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
EP2989097A4 (en) Improved processes for the preparation of linezolid using novel intermediates
IN2014MU00069A (ro)
MX2018011117A (es) Forma cristalina.
IN2012DE00957A (ro)

Legal Events

Date Code Title Description
FG4A Patent for invention issued